Rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, has demonstrated a good efficacy as treatment in patients with resistant Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but it is highly immunogenic due to its structure. Ocrelizumab (OCR) is a humanized anti-CD20 antibody, with higher tolerability and lower immunogenic profile compared to RTX. We present a case of refractory CIDP effectively treated with OCR switched from RTX after the development of anti-drug antibodies (ADA).
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab
Signoriello, Elisabetta;Bonavita, Simona;Lus, Giacomo
2020
Abstract
Rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, has demonstrated a good efficacy as treatment in patients with resistant Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but it is highly immunogenic due to its structure. Ocrelizumab (OCR) is a humanized anti-CD20 antibody, with higher tolerability and lower immunogenic profile compared to RTX. We present a case of refractory CIDP effectively treated with OCR switched from RTX after the development of anti-drug antibodies (ADA).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
